Syncona Share News (SYNC)

CORRECT (June 8): Syncona, Woodford And Arix Investee Plans ADS Offer

(Correcting Syncona and Woodford's shareholding value in Autolus Therapeutics following the ADS offering)LONDON (Alliance News) - Healthcare investor Syncona Ltd said Friday that its an

Syncona Investee Autolus Therapeutics Planning Nasdaq Listing (ALLIPO)

LONDON (Alliance News) - Healthcare investor Syncona Ltd on Tuesday noted the proposed listing of American depositary shares on the Nasdaq Global Market by investee Autolus Therapeutics said the

Syncona's Blue Earth Signs Licence For Prostate Cancer Imaging Agent

LONDON (Alliance News) - Life science focused investment trust Syncona Ltd said Wednesday its portfolio company Blue Earth Diagnostics has signed an exclusive licence for a radio-hybride prostate

Syncona's Nightstar 2017 Loss Widens On Research And Development Costs

LONDON (Alliance News) - Healthcare-focused investment company Syncona Ltd said on Wednesday that itsportfolio company Nightstar Therapeutics PLC reported a widened loss in as

Syncona Revises Investment Management Arrangement To Save Costs

LONDON (Alliance News) - Syncona Ltd said on Tuesday it has revised its investment management agreement with BACIT UK Ltd in order to reduce costs for has

WINNERS & LOSERS SUMMARY: Investors Lose Appetite For Just Eat

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.----------FTSE 100 - WINNERS----------Smurfit up it

Syncona And Arix Bioscience Notes Potential US IPO For Autolus (ALLIPO)

LONDON (Alliance News) - FTSE 250-listed healthcare investment company Syncona Ltd said on Tuesday its portfolio company Autolus Ltd, has filed a confidential submission of a

Syncona's Nightstar Begins NSR-REP1 Trial And Appoints New Director

LONDON (Alliance News) - Healthcare-focused investment company Syncona Ltd said on Monday that portfolio company Nightstar Therapeutics PLC has initiated a STAR Phase Three to

Syncona Takes Advice On FCA's Pooled Investment Marketing Restrictions

Small caps round-up: Imaginatik, Braveheart, Healthcare Locums...

Imaginatik has signed a new annual contract with a leading provider of healthcare services and medical research in the US. The contract has an initial start-up phase worth $0.12m in the current calendar year, followed by an ongoing annual contract worth $0.15m a year, with Imaginatik supplying it

Wednesday newspaper round-up: Cove, Vodafone, HSBC

HSBC has admitted for the first time it may face criminal charges that could see it hit with "significant" penalties stemming from a US investigation into alleged money-laundering by Britain's biggest bank. The bank is being investigated over possible violations of the US Bank Secrecy Act. HSBC also

Friday newspaper round-up: Greece, Oil, BoE

Germany's ruling parties are to introduce a resolution in parliament blocking any further boost to the EU's bail-out machinery, vastly complicating Greece's rescue package and risking a major clash with the International Monetary Fund. European solidarity is not an end in itself and should not be a

Synchronica signs partnership deal with NewPace

Mobile phone messaging technology group Synchronica has signed a letter of intent with Canada's NewPace Technology Development Inc to cooperate in the development, sales and marketing of a Rich Communication Suite (RCS) product. NewPace will license its current and future RCS technology to bid targ

Myriad asks if Synchronica has paid Nokia yet

Swiss mobile devices software firm Myriad, currently mounting a hostile bid for AIM-listed mobile phone messaging technology group Synchronica, has asked the UK group to confirm it has paid the first slug of money it owes to Nokia. On February 14th Synchronica, which bought the messaging business o

Synchronica lists myriad reasons to reject Swiss bid

Mobile phone messaging technology group Synchronica has been talking up the prospects of its turnaround plan as it fights off the unwelcome attentions of Swiss mobile devices software firm Myriad. The group said that its cost cutting programme, which it embarked upon late in 2011, will have some ef